Compare Amazon.com Inc (AMZN) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Danaher Corporation — how do they compare? Amazon.com Inc trades at $268.25 (market cap $2.94T), while Danaher Corporation trades at $205.86 (market cap $145.83B). The key difference: Amazon.com Inc is far larger — about 20.2× Danaher Corporation's market cap, and Danaher Corporation pays a 0.77% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | DHR | |
|---|---|---|
Market Cap | $2.94T | $145.83B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $242.05 |
52-Week Low | $198.79 | $161.91 |
Enterprise Value | $3.04T | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $278.09, up 1.32% with strong bullish momentum as technical indicators show the stock above key support levels. The company demonstrates robust fundamentals with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion, representing a 10.83% margin. Recent earnings beats in Q1 and Q2 2026 exceeded expectations significantly, while analyst sentiment remains overwhelmingly positive with 89% buy ratings.
Amazon's outlook remains favorable with continued revenue growth projected to $775.7 billion in 2026 and expanding profit margins. The primary investment opportunity lies in AWS growth and AI chip development, though risks include intense competition in e-commerce and significant capital expenditures. With a consensus price target of $333.86 representing 20% upside potential, the stock appears positioned for continued growth despite near-term overbought technical conditions.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
